Blood safety and the choice of anti‐hemophilic factor concentrate
Identifieur interne : 000F75 ( Main/Exploration ); précédent : 000F74; suivant : 000F76Blood safety and the choice of anti‐hemophilic factor concentrate
Auteurs : Leonard A. Valentino [États-Unis] ; Veeral M. Oza [États-Unis]Source :
- Pediatric Blood & Cancer [ 1545-5009 ] ; 2006-09.
English descriptors
- Teeft :
- Abnormal prion proteins, Administration cost, Allergic reactions, Antihemophilic factor, Avian virus, Baxter, Blood components, Blood donors, Blood product, Blood products, Blood safety, Blood safety monitoring, Blood supply, Blood transfusion, Blood transfusions, Blood transmission, Chronic infection, Chronic liver disease, Current status, Disease control, Donor screening, Excellent review, Factor viii, Haemophilia, Haemost, Hemolytic anemia, Hemophilia, Hemophilia patients, Hepatitis, Human albumin, Human parvovirus, Human proteins, Inactivation, Individual products, Infection, Infectious agent, Infectious disease, Infusion, Inhibitor, Inhibitor formation, International units, Joint disease, Kogenate, Liver disease, Microbiological threats, Mmwr, Mmwr morb, Mmwr series, Parvovirus, Pathogenic prion protein, Pediatr, Pediatr blood cancer, Plasma derivatives, Prion, Proc natl acad, Recombinant, Recombinant factor, Recombinant factor viii, Recombinant factor viii product, Recombinant factors, Recombinant products, Recombinant viii products, Recombinate, Recombinate study group, Respiratory syndrome, Right knee, Rush university, Senv, Several minutes, Severe hemophilia, Source plasma, Spongiform, Therapeutic products, Thromb, Thromb haemost, Transfusion, Transmissible spongiform encephalopathies, Travel history, Untreated, Untreated patients, Vaccine, Valentino, Variant disease, Vcjd, Viii, Viral, Viral infection, Viral safety, Virus, Virus infection, West nile virus, World federation, Young children.
Abstract
Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long‐term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia. Pediatr Blood Cancer 2006;47:245–254. © 2006 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/pbc.20895
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000428
- to stream Istex, to step Curation: 000408
- to stream Istex, to step Checkpoint: 000242
- to stream Main, to step Merge: 000F81
- to stream Main, to step Curation: 000F75
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Blood safety and the choice of anti‐hemophilic factor concentrate</title><author><name sortKey="Valentino, Leonard A" sort="Valentino, Leonard A" uniqKey="Valentino L" first="Leonard A." last="Valentino">Leonard A. Valentino</name></author><author><name sortKey="Oza, Veeral M" sort="Oza, Veeral M" uniqKey="Oza V" first="Veeral M." last="Oza">Veeral M. Oza</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2BE5E991971B9618D28E28A613AAF80EF37A0446</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/pbc.20895</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-XD9V1DHT-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000428</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000428</idno><idno type="wicri:Area/Istex/Curation">000408</idno><idno type="wicri:Area/Istex/Checkpoint">000242</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000242</idno><idno type="wicri:doubleKey">1545-5009:2006:Valentino L:blood:safety:and</idno><idno type="wicri:Area/Main/Merge">000F81</idno><idno type="wicri:Area/Main/Curation">000F75</idno><idno type="wicri:Area/Main/Exploration">000F75</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Blood safety and the choice of anti‐hemophilic factor concentrate</title><author><name sortKey="Valentino, Leonard A" sort="Valentino, Leonard A" uniqKey="Valentino L" first="Leonard A." last="Valentino">Leonard A. Valentino</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics and Department of Internal Medicine, Rush University Medical Center, Chicago</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>Correspondence address: Rush University Medical Center, 1653 West Congress Parkway, Chicago</wicri:cityArea></affiliation></author><author><name sortKey="Oza, Veeral M" sort="Oza, Veeral M" uniqKey="Oza V" first="Veeral M." last="Oza">Veeral M. Oza</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Illinois</region></placeName><wicri:cityArea>RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics and Department of Internal Medicine, Rush University Medical Center, Chicago</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Pediatric Blood & Cancer</title><title level="j" type="alt">PEDIATRIC BLOOD AND CANCER</title><idno type="ISSN">1545-5009</idno><idno type="eISSN">1545-5017</idno><imprint><biblScope unit="vol">47</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="245">245</biblScope><biblScope unit="page" to="254">254</biblScope><biblScope unit="page-count">10</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-09">2006-09</date></imprint><idno type="ISSN">1545-5009</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1545-5009</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormal prion proteins</term><term>Administration cost</term><term>Allergic reactions</term><term>Antihemophilic factor</term><term>Avian virus</term><term>Baxter</term><term>Blood components</term><term>Blood donors</term><term>Blood product</term><term>Blood products</term><term>Blood safety</term><term>Blood safety monitoring</term><term>Blood supply</term><term>Blood transfusion</term><term>Blood transfusions</term><term>Blood transmission</term><term>Chronic infection</term><term>Chronic liver disease</term><term>Current status</term><term>Disease control</term><term>Donor screening</term><term>Excellent review</term><term>Factor viii</term><term>Haemophilia</term><term>Haemost</term><term>Hemolytic anemia</term><term>Hemophilia</term><term>Hemophilia patients</term><term>Hepatitis</term><term>Human albumin</term><term>Human parvovirus</term><term>Human proteins</term><term>Inactivation</term><term>Individual products</term><term>Infection</term><term>Infectious agent</term><term>Infectious disease</term><term>Infusion</term><term>Inhibitor</term><term>Inhibitor formation</term><term>International units</term><term>Joint disease</term><term>Kogenate</term><term>Liver disease</term><term>Microbiological threats</term><term>Mmwr</term><term>Mmwr morb</term><term>Mmwr series</term><term>Parvovirus</term><term>Pathogenic prion protein</term><term>Pediatr</term><term>Pediatr blood cancer</term><term>Plasma derivatives</term><term>Prion</term><term>Proc natl acad</term><term>Recombinant</term><term>Recombinant factor</term><term>Recombinant factor viii</term><term>Recombinant factor viii product</term><term>Recombinant factors</term><term>Recombinant products</term><term>Recombinant viii products</term><term>Recombinate</term><term>Recombinate study group</term><term>Respiratory syndrome</term><term>Right knee</term><term>Rush university</term><term>Senv</term><term>Several minutes</term><term>Severe hemophilia</term><term>Source plasma</term><term>Spongiform</term><term>Therapeutic products</term><term>Thromb</term><term>Thromb haemost</term><term>Transfusion</term><term>Transmissible spongiform encephalopathies</term><term>Travel history</term><term>Untreated</term><term>Untreated patients</term><term>Vaccine</term><term>Valentino</term><term>Variant disease</term><term>Vcjd</term><term>Viii</term><term>Viral</term><term>Viral infection</term><term>Viral safety</term><term>Virus</term><term>Virus infection</term><term>West nile virus</term><term>World federation</term><term>Young children</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Hemophilia is a congenital disorder due to the deficiency of the activity of factor VIII (classical hemophilia A) or IX (Christmas disease or hemophilia B). Bleeding is common and may result in long‐term complications or even death. Bleeding may be treated or prevented by infusion of factor concentrates however these drugs are not without risk. Clinicians often feel ill prepared to provide accurate and impartial information regarding these drugs. This review will provide the reader with an historical yet up to date perspective on blood safety as it relates to the choice of concentrates to treat hemophilia. Pediatr Blood Cancer 2006;47:245–254. © 2006 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Valentino, Leonard A" sort="Valentino, Leonard A" uniqKey="Valentino L" first="Leonard A." last="Valentino">Leonard A. Valentino</name></region><name sortKey="Oza, Veeral M" sort="Oza, Veeral M" uniqKey="Oza V" first="Veeral M." last="Oza">Veeral M. Oza</name><name sortKey="Valentino, Leonard A" sort="Valentino, Leonard A" uniqKey="Valentino L" first="Leonard A." last="Valentino">Leonard A. Valentino</name><name sortKey="Valentino, Leonard A" sort="Valentino, Leonard A" uniqKey="Valentino L" first="Leonard A." last="Valentino">Leonard A. Valentino</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000F75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2BE5E991971B9618D28E28A613AAF80EF37A0446
|texte= Blood safety and the choice of anti‐hemophilic factor concentrate
}}
| This area was generated with Dilib version V0.6.33. |  |